Introduction: Blockade of the immune checkpoint programmed death receptor ligand-1
INTRODUCTION
Thymic epithelial tumors (TETs), including thymomas and thymic carcinomas, are rare, with an estimated incidence of 0.13 per 100,000 person-years in the United States. 1 The origin of these tumors, the thymus, is a complex immune organ critical in the creation of T-cells that carry either αβ T-cell receptors (TCRs) or γδ TCRs. 2 The thymus is essential in building the T-cell repertoire, with positive selection occurring when αβ T-cells contact peptide-major histocompatibility (MHC) complexes to produce CD4 + helper T-
cells (MHC II) and CD8 + cytotoxic T-cells (MHC I). The thymus is also essential for
immune homeostasis and self-tolerance via negative selection. T cells are removed when they exceed a binding threshold for the MHC-peptide complex in the thymic medulla, and natural regulatory T-cells are created via induction of transcription factor forkhead box P3 (FoxP3). 3 Given the critical role of the thymus in immune function, it is not surprising that TETs are associated with autoimmune conditions like myasthenia gravis 4 and pure red cell aplasia 5 , and a higher rate of secondary malignancies. 6 These paraneoplastic conditions are associated with disruption in the balance of regulatory T-cells and effector T-cells in both the peripheral blood 7 and within the tumor microenvironment. 8, 9 As a proof-ofconcept, after thymectomy, it has been shown that this immune dysfunction improves; for example, disproportionately high levels of peripheral blood cytotoxic CD45 + CD8 + Tcells implicated in autoimmunity significantly decrease. population. 13 PD-L1 expression has also been found on thymic epithelial cells at the RNA and protein level. 14, 15 PD-1 expression in the thymus is induced at various stages of thymocyte development prior to T-cell clonal selection and is critical via its interaction with PD-L1 for the regulation of positive selection and the final T-cell repertoire. 16, 17 Although the PD-1/PD-L1 interaction is critical in peripheral tolerance, given its key role in positive selection, it may also play an important role in central tolerance. 18, 19 In a small series of TETs reported by Brown et Given the importance of PD-1 and PD-L1 within the normal thymus and the emergence of PD-L1 as a potential predictive biomarker for anti-PD-1 and anti-PD-L1 cancer immunotherapy, we examined PD-L1 expression by IHC in a TET tissue microarray (TMA).
MATERIALS AND METHODS
This research was performed under an institutional review board approved protocol.
Formalin-fixed, paraffin-embedded tissue samples of TETs were obtained from surgical pathology at Stanford University (Stanford, CA). A TMA was constructed from 69 TETs and 17 thymic controls (including 9 paired non-neoplastic thymuses adjacent to tumor).
Two additional paired controls and two unpaired controls were not included in the analysis as insufficient tissue remained on the stained levels. To maximize the number of thymic epithelial cells, three 600-μm cores were selected from each case. These cores were generally selected from centrally located areas of the tumors. Majority of the cases had representative tissue in the TMA from initial diagnosis, except for six cases that had tissue from recurrence, including from a paravertebral mass, brain, diaphragmatic base, pleura and the remaining two from the thymus/mediastinal mass. In addition, one stage 
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RESULTS
Baseline Characteristics
There were a total of 69 cases of TETs ( 
TETs Stain Intensely and Diffusely for PD-L1, with Staining Found Mostly on Epithelial Cells and in a Minority of Tumor-Associated Lymphocytes (TALs)
The majority of PD-L1 staining was found on TET epithelial cells rather than TALs.
When staining was present, in almost all cases, it was diffuse (> 50% of cells in the core).
PD-L1 staining was both membranous and cytoplasmic in all cases. Only two cases had nuclear staining in addition. There were no PD-L1 intensity scores of 0 in either TETs or controls. PD-L1 high scores were significantly more frequent in TETs than controls: 68.1%
(n=47/69) vs. 17.6% (n=3/17), respectively (p=0.0036) (Figure 1a and 1b) . There was
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also a trend for a higher proportion of PD-L1 high scores in TETs when compared to their paired adjacent non-neoplastic thymus (p=0.09). Only 14.8% of TALs from TETs (n=8/54) ( Figure 1c ) and 29.4% of lymphocytes from controls (n=5/17) stained for PD-L1. In almost all cases (except one), PD-L1 intensity of TALs was weak with a score of 2.
There was also no correlation between PD-L1 intensity on epithelial cells and TAL density (p=0.31).
Characteristics were examined between PD-L1 high TETs and PD-L1 low TETs ( Table 3) . 
More Intense PD-L1 Staining Associated with Higher Grade WHO Histologies
There was a statistically significant correlation between PD-L1 intensity and WHO (Figure 2) . staining on TALs in a proportional hazards model.
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Tumor-Associated Lymphocytes (TALs) Are Not Independently Prognostic and Reflect
WHO Histology
The abundance of TALs to some degree defines TET histology according to the WHO classification. 23 
DISCUSSION
Immune checkpoint blockade of PD-1 or PD-L1 is very promising, with activity across many tumor types including melanoma, renal cell carcinoma, and lung cancer. worse clinical outcomes. In our series, the intensity of membranous or cytoplasmic epithelial staining was most important. To our knowledge, this is the largest set of TETs examined for PD-L1 expression and the first to study the impact of PD-L1 expression on clinical outcomes in this rare tumor type. Expression of PD-L1 in TETs is intriguing because TETs are frequently associated with autoimmune conditions and immune dysfunction 4, 7 , and in the normal thymus, the PD-1/PD-L1 interaction is critical for thymocyte selection. 16, 17 In our series, PD-L1 high expression was a poor prognostic risk factor. This was most likely because of its significant correlation with WHO histology, with PD-L1 high TETs associated with more aggressive histologies including type B3 thymomas and thymic carcinomas. This was not a perfect correlation, with type B1, B2, and C TETs containing a similar percentage of PD-L1 high scores. In this cohort, PD-L1 high TETs also had a trend for association with other poor prognostic features including higher stage (p=0.056) and incomplete resection status (p=0.053). In addition, more aggressive WHO histologies had a statistically significant correlation with worse pathologic Masaoka-Koga stage (p<0.0001) and incomplete resection status (p<0.0001). In the multivariate models adjusting for stage or resection status, the PD-L1 intensity score had a trend for being an independent prognostic effect, at least for overall survival.
This association with PD-L1 expression and more aggressive histology has been shown in other tumor types including non-small cell lung cancer, where those with sarcomatoid features had a higher percentage of PD-L1 expression and intensity compared to other
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subtypes. 26 This has also been shown in sarcomatoid malignant mesothelioma 27 and higher grades of bladder cancer. 28 PD-L1 expression in many series has a variable impact on prognosis depending on the cancer type and the study. For example, PD-L1 expression has been associated with a poor prognosis in breast cancer 29 and improved prognosis in mismatch-repair proficient colorectal cancer 30 and lung cancer. 31 However, even within a cancer type, PD-L1 expression may have a contradictory impact on prognosis. 32 There are currently several variables in PD-L1 testing including: 1) the type of tissue stained performance of PD-L1 antibodies within a single institution. 31, 33 This was confirmed in our experience. A specific limitation in our study was that only one pathologist reviewed the PD-L1 score; however, the pathologist was blinded to both clinical outcomes and sample identity.
The majority of the PD-1 and PD-L1 inhibitors in development are also co-developing a companion diagnostic test of PD-L1 by IHC, as this is emerging as a potential predictor of response to these therapies. 12, [34] [35] [36] [37] The predictive ability of PD-L1 by IHC has mainly been explored in relation to objective response rate (ORR) by RECIST 1. some tumor types 34, 35 , and its predictive capability can vary depending if positivity is defined on tumor cells or TILs. 36, 37 Many of these studies suffer from examining tumors that have been pre-treated, are retrospectively collected, and only represent a subset of the cohort. Therefore, this biomarker is being validated prospectively in clinical trials.
Unlike the current definitions of PD-L1 positivity being employed in clinical trials, given the diffuse staining we observed on TETs, our scoring system heavily relied on staining intensity rather than a threshold percentage of cells staining positive. Despite finding epithelial cell/tumor cell PD-L1 staining of TETs to be most important in our study, our ability to evaluate the prognostic significance of PD-L1 staining on TALs was limited by the small sample size and the high rate of censoring for survival outcomes.
Unlike other solid tumors such as ovarian and colorectal cancer where TILs have prognostic value 38, 39 , TETs are defined histologically by their epithelial atypia and abundance of lymphocytes. Abundant lymphocytes are seen in type AB, B1, and B2
TETs and are a minor component in type A, B3, and most C TETs, with type B3 and C being more aggressive histologies. 23 In our series, not surprisingly, there was a strong correlation between TALs and histology in a mostly expected distribution. TALs were not an independent prognostic feature in a proportional hazards model that adjusted for WHO histology.
Unfortunately, the standard of care in the treatment of TETs is relatively unrefined due to the rare nature of these diseases. Generally, when resectable, complete resections predict for the longest survival. 40 In the locally advanced/unresectable or metastatic first-line setting, platinum-based therapies are used with palliative intent only 41, 42 , and there has been limited utility of novel targeted therapies to date. Given the emergence of PD-L1 as a promising predictive biomarker and the diffuse staining of PD-L1 seen in TETs in our study, the next step is to conduct a clinical trial with anti-PD-1 or anti-PD-L1 therapy in this rare tumor type. Generally, anti-PD-1 and anti-PD-L1 therapies are well tolerated, with a unique side effect of immune-related adverse events (iAEs). 12, 24, 43 However, when considering this therapy in TETs, caution should be taken given the high burden of associated autoimmune disorders such as myasthenia gravis. 4 In conclusion, our study showed high PD-L1 expression in TETs, with higher staining b Initial pathologic Masaoka-Koga stage was unknown in 4 patients but these patients were known not to have metastatic disease at initial diagnosis. One stage IVA patient had a radical resection and was considered not to have metastases at diagnosis. Of the four unknown stages, all had a prolonged time from initial diagnosis to recurrence (range: 42.3-219.6 months). c A micronodular thymoma with lymphoid stroma was classified as type A; 3 classified as B1 were mixed B1/B2; 1 classified as B3 was mixed B2/B3; and 1 classified as C was mixed B3/C. d Those cases with metastases at diagnosis were all stage IV. There was one stage IV case without metastases at diagnosis because of radical resection that was performed. However, the remaining are non-metastatic stage I-III cases. e 2 of the sternotomies were performed with a thoracotomy and 2 additional were performed with a VATS. f Of the R2 resections, stages were as follows: 3 IVA, 2 IVB, and 5 III. Of the R1 resections, stages were as follows: 3 IIA, 2 IIB, 3 III, and 1 IVA. g Of those cases that received induction therapy, 11 had advanced stage III-IV disease. Of those cases that received adjuvant radiation, 13 had advanced stage III-IV disease and 13 had R1 or R2 resection status. Chi-square or Fisher's exact tests were performed to determine differences in characteristics between PD-L1 high and PD-L1 low TETs. Two-sided p-values < 0.05 are statistically significant and indicated by (*). Two-sided p-values < 0.1 indicate a trend for significance and are indicated by ( + ) a, There were 4 cases that were not evaluable for the following characteristics because of unknown details at initial diagnosis including (3 PD-L1
high and 1-PD-L1 low ): stage, resection status, completeness of thymectomy, and surgical approach. Regardless, all categories should add up to ~100%.
